By Richard W. Hare, DC, NASM-CES, NASM-PES, CSCS
Founder and Developer, Ageless Performance Project
September 30, 2026
After 40, many adults want more than a lower number on the scale. They want less abdominal fat, better muscle definition, and the strength and energy to keep doing what they enjoy.
That interest has brought growing attention to tesamorelin and CJC-1295/ipamorelin—peptides discussed for their effects on the growth hormone system. Their proposed benefits sound appealing, but these compounds have different evidence, different formulations, and important limitations.
Tesamorelin has clinical evidence for reducing visceral fat in specific patient populations. CJC-1295 has demonstrated effects on growth hormone and IGF-1, but those hormone changes do not establish that a CJC-1295/ipamorelin combination produces meaningful body recomposition or slows aging. [1–5]
Why the growth hormone system attracts interest
Growth hormone helps regulate metabolism and stimulates production of insulin-like growth factor 1, or IGF-1. These signals influence tissue growth and how the body uses nutrients. Tesamorelin and CJC-1295 act through the growth hormone-releasing hormone pathway; ipamorelin acts through the ghrelin receptor pathway. [1,4,6]
The proposed rationale is that stimulating these pathways could support fat metabolism and lean tissue. However, biological plausibility is an early step in research. A higher laboratory value does not, by itself, demonstrate stronger muscles, better recovery, or a longer life.
Tesamorelin: the clearest evidence concerns visceral fat
Tesamorelin is a synthetic growth hormone-releasing hormone analog. FDA-approved tesamorelin products are indicated for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. They are not approved as general weight-loss or anti-aging treatments. [1]
In one randomized trial, visceral adipose tissue decreased by 15.2% after 26 weeks of tesamorelin, compared with a 5.0% increase in the placebo group. These were changes in measured visceral fat—not a 15% reduction in body weight or total body fat. [2]
An extension study found an approximately 18% reduction from baseline after 52 weeks of continued treatment. Visceral fat reaccumulated in participants who switched from tesamorelin to placebo, suggesting that the effect generally requires continued therapy. [3]
There is also research outside HIV-associated lipodystrophy. A randomized trial in selected adults with obesity and reduced growth hormone secretion reported improvement in visceral fat and some cardiovascular risk markers. This supports further investigation, but does not establish routine treatment for everyone with abdominal fat or prove fewer heart attacks or longer survival. [7]
Visceral fat is different from the fat you can pinch
Visceral fat surrounds internal organs; subcutaneous fat sits beneath the skin. A treatment that reduces one depot may have little effect on another.
Tesamorelin’s targeted effect helps explain why a person could have less visceral fat without substantial scale-weight loss. Its prescribing information describes a weight-neutral effect. A change in waist size or appearance also cannot precisely identify how much visceral fat changed. [1,2]
CJC-1295: what “with DAC” and “without DAC” mean
DAC stands for drug affinity complex. It is a modification that allows the CJC peptide to bind to albumin, a blood protein, extending its time in circulation. [4,5]
Products marketed as “CJC-1295 without DAC” are commonly described as modified GRF(1–29), a shorter-acting related peptide. Naming is inconsistent, so the exact molecule matters. Results from a study of long-acting CJC-1295 should not automatically be applied to a product sold under a similar name without DAC. [5]
| Feature | CJC-1295 with DAC | Products marketed as CJC-1295 without DAC |
|---|---|---|
| Duration | Prolonged exposure through albumin binding | Shorter exposure without the albumin-binding modification |
| Human research | Early trials demonstrate sustained increases in GH and IGF-1 | Those DAC trial findings do not establish the effects of the shorter-acting formulation |
| Fat-loss interpretation | Hormone increases do not prove visceral-fat reduction | Shorter activity does not prove superior fat loss or safety |
| Anti-aging interpretation | No established lifespan or aging-reversal benefit | No established lifespan or aging-reversal benefit |
The “with or without DAC” distinction refers to the CJC component, not to ipamorelin.
In early human trials, long-acting CJC-1295 increased growth hormone and IGF-1 for several days. These studies were designed primarily to assess hormone responses and short-term tolerability, rather than demonstrate durable fat loss, muscle strength, or longevity. [4]
Although the shorter-acting formulation is often promoted as more “pulsatile,” research found that growth hormone pulses persisted with long-acting CJC-1295 as well. The claim that DAC necessarily eliminates normal pulsatility is too simplistic. [8]
Why combine CJC-1295 with ipamorelin?
Ipamorelin is a growth hormone secretagogue: a compound that stimulates growth hormone release. Because it acts through a different receptor pathway from CJC-1295, the proposed combination aims to amplify the hormonal response. [5,6]
This mechanistic rationale has fueled claims about fat loss, muscle gain, sleep, and recovery. However, robust human trials have not established that either commonly marketed CJC-1295/ipamorelin formulation reliably produces these outcomes in otherwise healthy adults. There is also no strong head-to-head evidence establishing which combination is best for body recomposition or visceral fat. [5]
Early ipamorelin selectivity research is largely preclinical. It should not be treated as proof that the combination is free from unwanted hormonal effects or safe for long-term use. [6]
Body recomposition: measure outcomes beyond hormone levels
Body recomposition means reducing fat while preserving or increasing muscle. Evaluating a proposed treatment therefore requires more than checking GH or IGF-1.
Useful questions include:
- Did fat mass decrease, and which fat depot changed?
- Did muscle strength or physical function improve?
- Was an increase in measured lean mass influenced by fluid retention?
- Were benefits maintained, and what happened after treatment stopped?
- Did glucose control or other health measures worsen?
Tesamorelin’s visceral-fat findings cannot be transferred to CJC-1295/ipamorelin simply because both affect the growth hormone system. Similarly, a reported increase in lean mass is not automatically an increase in functional muscle. [1–5]
Do these peptides have anti-aging effects?
“Anti-aging” can mean anything from looking leaner to preventing disability or extending life. Those are different outcomes and require different evidence.
None of these peptides has been shown to reverse human aging or extend human lifespan. The available studies do not establish those outcomes. [1,4,5]
A systematic review of growth hormone treatment in healthy older adults found modest changes in body composition alongside more adverse effects, and concluded that GH could not be recommended as an anti-aging therapy. This review studied growth hormone itself, rather than these peptide combinations, so it provides context rather than a direct assessment of their safety or efficacy. [9]
For APP, healthy aging means maintaining strength, mobility, metabolic health, and independence. A promising biological mechanism deserves investigation; an anti-aging claim needs evidence of meaningful human benefit.
Safety and regulatory status matter
Tesamorelin can cause elevated IGF-1, fluid retention, joint discomfort, injection-site reactions, and impaired glucose tolerance or diabetes. Its labeling calls for monitoring glucose and IGF-1. It is contraindicated in pregnancy, active malignancy, certain disruptions of the hypothalamic-pituitary axis, and known hypersensitivity. Long-term cardiovascular safety has not been established. [1]
CJC-1295 and ipamorelin are not FDA-approved medications. FDA has identified concerns about immune reactions and peptide impurities, and reports associated with CJC-1295 include increased heart rate and systemic vasodilatory reactions. [5,10]
For ipamorelin, FDA notes serious adverse events, including deaths, in an intravenous gastric-motility study. That context differs from subcutaneous wellness use and does not establish causation, but safety information for other injectable routes remains insufficient. [10]
Compounding does not confer FDA approval. Likewise, “research use only” labeling does not establish suitability for human treatment. The exact product, route, evidence, and current regulatory requirements all deserve discussion with a licensed medical professional.
Explore your options through APP telemedicine services
Ageless Performance Project offers education and access to independent telemedicine pathways for medical weight management, men’s hormone health, and peptide therapy evaluation. APP helps adults over 40 understand their options and ask better questions; medical evaluation, treatment decisions, and prescriptions are provided by independent licensed healthcare professionals. [11]
If abdominal fat, recovery, or changes in performance concern you, a consultation can help clarify possible causes and appropriate next steps. Ask about the evidence for your specific situation, approved alternatives, monitoring, and realistic outcomes.
Explore APP consultation and telemedicine options. An evaluation does not guarantee eligibility for a particular treatment or the availability of any peptide discussed here.
Performance has no expiration date. Better decisions start with better evidence.
This article provides general education and is not individualized medical advice. APP may receive compensation from certain partner referrals. Treatment suitability, availability, and prescribing are determined by the independent medical provider.
References
- EGRIFTA WR: current prescribing information, DailyMed.
- Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. 2007.
- Falutz J, et al. Long-term safety and effects of tesamorelin in HIV patients with abdominal fat accumulation. AIDS. 2008.
- Teichman SL, et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adults. Journal of Clinical Endocrinology & Metabolism. 2006.
- FDA. CJC-1295-related bulk drug substances: Pharmacy Compounding Advisory Committee briefing document. December 2024. This advisory briefing is not itself a final regulatory determination.
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998.
- Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial. Journal of Clinical Endocrinology & Metabolism. 2012.
- Ionescu M, Frohman LA. Pulsatile secretion of GH persists during continuous stimulation by CJC-1295. Journal of Clinical Endocrinology & Metabolism. 2006.
- Liu H, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Annals of Internal Medicine. 2007.
- FDA. Certain bulk drug substances for use in compounding that may present significant safety risks. Accessed September 30, 2026.
- Ageless Performance Project and consultation pathways. Accessed September 30, 2026.
